Pfizer Inc (PFE)
Working capital turnover
| Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | ||
|---|---|---|---|---|---|---|
| Revenue | US$ in thousands | 63,627,000 | 58,496,000 | 100,330,000 | 81,288,000 | 41,908,000 |
| Total current assets | US$ in thousands | 50,358,000 | 43,333,000 | 51,259,000 | 59,693,000 | 35,067,000 |
| Total current liabilities | US$ in thousands | 42,995,000 | 47,794,000 | 42,138,000 | 42,671,000 | 25,920,000 |
| Working capital turnover | 8.64 | — | 11.00 | 4.78 | 4.58 |
December 31, 2024 calculation
Working capital turnover = Revenue ÷ (Total current assets – Total current liabilities)
= $63,627,000K ÷ ($50,358,000K – $42,995,000K)
= 8.64
Pfizer Inc's working capital turnover has shown a positive trend over the years, increasing from 4.58 in December 31, 2020, to 4.78 in December 31, 2021, and then significantly jumping to 11.00 in December 31, 2022. This indicates that the company is efficiently utilizing its working capital to generate revenue. However, the absence of a value for December 31, 2023, obscures the complete trend analysis. The working capital turnover ratio then decreased to 8.64 by the end of December 31, 2024, still reflecting strong efficiency in working capital management. Overall, the trend suggests that Pfizer Inc has been effectively utilizing its working capital to support its operations and generate revenue during the period under review.
Peer comparison
Dec 31, 2024